Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAAA | Q02083 | 11/20 | 0.62 |
| ▸ | ASAH1 | Q13510 | 1/20 | 0.57 |
| ▸ | CTSL | P07711 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4078569 | 1.00 | NAAA (0.62) | NAAAASAH1CTSLALDH1A1GAA | |
| SCHEMBL4077965 | 1.00 | NAAA (0.62) | NAAAASAH1CTSLALDH1A1GAA | |
| SCHEMBL4087794 | 0.96 | NAAA (0.61) | NAAAASAH1CTSLALDH1A1GAA | |
| SCHEMBL4081547 | 0.96 | NAAA (0.61) | NAAAASAH1CTSLALDH1A1GAA | |
| SCHEMBL10719082 | 0.96 | NAAA (0.61) | NAAAASAH1CTSLALDH1A1GAA | |
| SCHEMBL3734489 | 0.92 | NAAA (0.65) | NAAAASAH1CTSLALDH1A1GAA | |
| SCHEMBL4074285 | 0.92 | NAAA (0.65) | NAAAASAH1CTSLALDH1A1GAA | |
| SCHEMBL4084617 | 0.92 | NAAA (0.65) | NAAAASAH1CTSLALDH1A1GAA | |
| SCHEMBL6200442 | 0.89 | NAAA (0.57) | NAAAASAH1ALDH1A1 | |
| SCHEMBL6200454 | 0.89 | NAAA (0.57) | NAAAASAH1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376436-B2 | 2-(pyridin-2yl)-1, 7-diaza-spiro [4.4] nonane-6-one compound as voltage-gated sodium channels modulators | Convergence Pharmaceuticals Limited (GB) | 2016-06-28 | — | — | US | disclosed |
| EP-2794612-B1 | 2-(PYRIDIN-2YL)-1,7-DIAZA-SPIRO[4.4]NONANE-6-ONE COMPOUNDS AS VOLTAGE-GATED SODIUM CHANNELS MODULATORS | CONVERGENCE PHARMACEUTICALS (GB) | 2016-04-06 | — | — | EP | disclosed |
| US-20150225400-A1 | 2 - (PYRIDIN- 2YL)- 1, 7 -DIAZA-SPIRO [4.4] NONANE- 6 -ONE COMPOUND AS VOLTAGE-GATED SODIUM CHANNELS MODULATORS | Convergence Pharmaceuticals Limited (GB) | 2015-08-13 | — | — | US | disclosed |
| EP-2794612-A1 | 2 - (PYRIDIN- 2YL) - 1, 7 -DIAZA- SPIRO [4.4]NONANE- 6 -ONE COMPOUNDS AS VOLTAGE - GATED SODIUM CHANNELS MODULATORS | Convergence Pharmaceuticals Limited (GB) | 2014-10-29 | — | — | EP | disclosed |
| WO-2013093497-A1 | 2 - (PYRIDIN- 2YL) - 1, 7 -DIAZA- SPIRO [4.4] NONANE- 6 -ONE COMPOUNDS AS VOLTAGE - GATED SODIUM CHANNELS MODULATORS | Convergence Pharmaceuticals Limited (GB) | 2013-06-27 | — | — | WO | disclosed |
| US-7531657-B2 | Method for preparing sulphostin and analogue thereof or preparation intermediate thereof | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2009-05-12 | — | — | US | disclosed |
| US-7524863-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524863-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2009-04-28 | — | — | US | disclosed |
| US-7157470-B2 | Sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-02 | — | — | US | disclosed |
| EP-1501798-A4 | SULFONYLAMINOVALEROLAC TAMS AND DERIVATIVES THEREOF AS FACTOR Xa INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2006-11-22 | — | — | EP | disclosed |
| EP-1184388-B1 | SULPHOSTIN ANALOGUES AND PROCESSES FOR THE PREPARATION OF SULPHOSTIN AND ANALOGUES THEREOF | ZAIDAN HOJIN BISEIBUTSU (JP) | 2003-07-30 | — | — | EP | disclosed |
| US-6579989-B1 | Dipeptidylpeptidase IV inhibitors; hormone and immune modu-laters; anti-HIV and antiallergenic agents | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 2003-06-17 | — | — | US | disclosed |
| US-6534495-B1 | Anticoagulants that prevent thrombin-related diseases. | AKZO NEBEL (NL) | 2003-03-18 | — | — | US | disclosed |
| EP-1184388-A1 | SULPHOSTIN ANALOGUES AND PROCESSES FOR THE PREPARATION OF SULPHOSTIN AND ANALOGUES THEREOF | ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) | 2002-03-06 | — | — | EP | disclosed |
| CN-1254345-A | Serine protease inhibitors | AKZO NOBEL NV (NL) | 2000-05-24 | — | — | CN | disclosed |
| EP-0979240-A1 | SERINE PROTEASE INHIBITORS | Akzo Nobel N.V. (NL) | 2000-02-16 | — | — | EP | disclosed |
| WO-1998050420-A1 | SERINE PROTEASE INHIBITORS | AKZO NOBEL N.V. (NL) | 1998-11-12 | — | — | WO | disclosed |
| US-4598071-A | ANGIOTENSIN INHIBITORS/ | E. R. SQUIBB & SONS, INC. (US) | 1986-07-01 | — | — | US | disclosed |
| US-4567167-A | INHIBITOR OF ANGIOTENDIN CONVERTING ENZYME | E. R. SQUIBB & SONS, INC. (US) | 1986-01-28 | — | — | US | disclosed |
| US-4533661-A | Certain 3-phosphinyl-amino-2-oxo-1H-azepine-1-acetic acid derivatives having anti-hypertensive activity | E. R. SQUIBB & SONS, INC. (US) | 1985-08-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225400-A1 | 2 - (PYRIDIN- 2YL)- 1, 7 -DIAZA-SPIRO [4.4] NONANE- 6 -ONE COMPOUND AS VOLTAGE-GATED SODIUM CHANNELS MODULATORS | SCN1A, SCN2A, SCN1B | NAAA 1700/4885ASAH1 2330/4885CTSL 4704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.